Xeris Biopharma Holdings Inc
XERS7.370USD
+0.160+2.22%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.22BMarket Cap
LossP/E TTM
More Details of Xeris Biopharma Holdings Inc Company
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
Xeris Biopharma Holdings Inc Info
Ticker SymbolXERS
Company nameXeris Biopharma Holdings Inc
IPO dateJun 21, 2018
CEOShannon (John P)
Number of employees394
Security typeOrdinary Share
Fiscal year-endJun 21
Address1375 West Fulton Street, Suite 1300
CityCHICAGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code60607
Phone18444455704
Websitehttps://www.xerispharma.com/
Ticker SymbolXERS
IPO dateJun 21, 2018
CEOShannon (John P)
Company Executives of Xeris Biopharma Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin McCulloch
Mr. Kevin McCulloch
President, Chief Operating Officer
President, Chief Operating Officer
922.37K
-0.08%
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
480.59K
-3.35%
Dr. Jeffrey W. Sherman, M.D.
Dr. Jeffrey W. Sherman, M.D.
Independent Director
Independent Director
174.59K
+2.83%
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Independent Director
Independent Director
164.14K
+43.80%
Ms. Marla S. Persky, J.D.
Ms. Marla S. Persky, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
98.37K
-13.61%
Ms. Dawn Halkuff
Ms. Dawn Halkuff
Independent Director
Independent Director
70.41K
-37.64%
Mr. Steven M. Pieper
Mr. Steven M. Pieper
Chief Financial Officer
Chief Financial Officer
--
--
Mr. James Brady
Mr. James Brady
Independent Director
Independent Director
--
--
Mr. John P. Shannon
Mr. John P. Shannon
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Allison Wey
Ms. Allison Wey
Senior Vice President - Investor Relations & Corporate Communications
Senior Vice President - Investor Relations & Corporate Communications
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin McCulloch
Mr. Kevin McCulloch
President, Chief Operating Officer
President, Chief Operating Officer
922.37K
-0.08%
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
480.59K
-3.35%
Dr. Jeffrey W. Sherman, M.D.
Dr. Jeffrey W. Sherman, M.D.
Independent Director
Independent Director
174.59K
+2.83%
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Independent Director
Independent Director
164.14K
+43.80%
Ms. Marla S. Persky, J.D.
Ms. Marla S. Persky, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
98.37K
-13.61%
Ms. Dawn Halkuff
Ms. Dawn Halkuff
Independent Director
Independent Director
70.41K
-37.64%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
By BusinessUSD
Name
Revenue
Proportion
Product revenue -Recorlev
31.44M
43.95%
Product revenue - Gvoke
23.47M
32.80%
Product revenue - Keveyis
11.48M
16.05%
Royalty, contract and other revenue
3.83M
5.36%
Other product revenue
1.31M
1.83%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product revenue -Recorlev
31.44M
43.95%
Product revenue - Gvoke
23.47M
32.80%
Product revenue - Keveyis
11.48M
16.05%
Royalty, contract and other revenue
3.83M
5.36%
Other product revenue
1.31M
1.83%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.26%
The Vanguard Group, Inc.
5.90%
D. E. Shaw & Co., L.P.
3.52%
Geode Capital Management, L.L.C.
2.50%
State Street Investment Management (US)
2.25%
Other
79.57%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.26%
The Vanguard Group, Inc.
5.90%
D. E. Shaw & Co., L.P.
3.52%
Geode Capital Management, L.L.C.
2.50%
State Street Investment Management (US)
2.25%
Other
79.57%
Shareholder Types
Shareholders
Proportion
Investment Advisor
23.78%
Investment Advisor/Hedge Fund
16.54%
Hedge Fund
12.84%
Research Firm
4.79%
Individual Investor
3.86%
Pension Fund
0.84%
Sovereign Wealth Fund
0.34%
Bank and Trust
0.32%
Family Office
0.07%
Other
36.63%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
365
90.49M
54.54%
-11.44M
2025Q2
336
95.54M
59.64%
+13.83M
2025Q1
335
93.86M
58.93%
+12.36M
2024Q4
297
71.87M
48.21%
-8.26M
2024Q3
280
71.79M
48.23%
-5.89M
2024Q2
269
66.65M
44.99%
-10.81M
2024Q1
284
69.70M
49.68%
-4.28M
2023Q4
271
65.59M
47.45%
-7.22M
2023Q3
264
62.48M
45.27%
-15.54M
2023Q2
276
65.86M
49.56%
-15.25M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
10.16M
6.29%
+561.21K
+5.85%
Jun 30, 2025
The Vanguard Group, Inc.
9.82M
6.08%
+1.71M
+21.05%
Jun 30, 2025
D. E. Shaw & Co., L.P.
3.84M
2.38%
+783.03K
+25.65%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.65M
2.26%
+244.86K
+7.19%
Jun 30, 2025
State Street Investment Management (US)
3.78M
2.34%
+457.94K
+13.77%
Jun 30, 2025
Qube Research & Technologies Ltd
3.09M
1.91%
+1.25M
+67.51%
Jun 30, 2025
Morgan Stanley & Co. LLC
2.61M
1.62%
-532.53K
-16.93%
Jun 30, 2025
Nuveen LLC
2.54M
1.57%
+320.39K
+14.42%
Jun 30, 2025
Driehaus Capital Management, LLC
2.07M
1.28%
+659.53K
+46.72%
Jun 30, 2025
Two Sigma Investments, LP
2.27M
1.41%
+455.53K
+25.08%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
2.04%
Virtus LifeSci Biotech Clinical Trials ETF
1.49%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.29%
Inspire Fidelis Multi Factor ETF
1.2%
Invesco Dorsey Wright Healthcare Momentum ETF
0.98%
Invesco Dorsey Wright SmallCap Momentum ETF
0.52%
iShares Micro-Cap ETF
0.29%
Vanguard US Momentum Factor ETF
0.28%
Even Herd Long Short ETF
0.28%
Federated Hermes MDT Small Cap Core ETF
0.25%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.04%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.49%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.29%
Inspire Fidelis Multi Factor ETF
Proportion1.2%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.98%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.52%
iShares Micro-Cap ETF
Proportion0.29%
Vanguard US Momentum Factor ETF
Proportion0.28%
Even Herd Long Short ETF
Proportion0.28%
Federated Hermes MDT Small Cap Core ETF
Proportion0.25%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Xeris Biopharma Holdings Inc?
The top five shareholders of Xeris Biopharma Holdings Inc are:
BlackRock Institutional Trust Company, N.A. holds 10.16M shares, accounting for 6.29% of the total shares.
The Vanguard Group, Inc. holds 9.82M shares, accounting for 6.08% of the total shares.
D. E. Shaw & Co., L.P. holds 3.84M shares, accounting for 2.38% of the total shares.
Geode Capital Management, L.L.C. holds 3.65M shares, accounting for 2.26% of the total shares.
State Street Investment Management (US) holds 3.78M shares, accounting for 2.34% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 10.16M shares, accounting for 6.29% of the total shares.
The Vanguard Group, Inc. holds 9.82M shares, accounting for 6.08% of the total shares.
D. E. Shaw & Co., L.P. holds 3.84M shares, accounting for 2.38% of the total shares.
Geode Capital Management, L.L.C. holds 3.65M shares, accounting for 2.26% of the total shares.
State Street Investment Management (US) holds 3.78M shares, accounting for 2.34% of the total shares.
What are the top three shareholder types of Xeris Biopharma Holdings Inc?
The top three shareholder types of Xeris Biopharma Holdings Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
D. E. Shaw & Co., L.P.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
D. E. Shaw & Co., L.P.
How many institutions hold shares of Xeris Biopharma Holdings Inc (XERS)?
As of 2025Q3, 365 institutions hold shares of Xeris Biopharma Holdings Inc, with a combined market value of approximately 90.49M, accounting for 54.54% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -5.10%.
What is the biggest source of revenue for Xeris Biopharma Holdings Inc?
In FY2025Q2, the Product revenue -Recorlev business generated the highest revenue for Xeris Biopharma Holdings Inc, amounting to 31.44M and accounting for 43.95% of total revenue.
